Slower visual field loss in patients with primary open-angle glaucoma was linked to greater physical activity, suggesting ...

Disc hemorrhage location was associated with areas of clustered visual field progression in patients with primary open-angle ...

Open-angle glaucoma represents one of the most prevalent causes of irreversible sight loss globally. The principal aim of treatment is to lower intraocular pressure (IOP) to slow the progression ...

Use of nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) is associated with an increased risk for primary open-angle glaucoma (POAG), according to a study published online June 20 ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma ...

Diorasis Therapeutics has partnered with Northway Biotech to establish a scalable cGMP production process for DTx’s lead ...

Nicox and Kowa entered into an agreemen in February 2024, in which Kowa was granted exclusive Japanese rights to develop and ...

A new study suggests that a specific combination of vitamins may help slow down damage to the optic nerve in people with ...

Diorasis Therapeutics & Northway Biotech partner to develop and manufacture AAV gene therapy for glaucoma: Boston, Massachusetts Thursday, July 31, 2025, 16:00 Hrs [IST] Diorasis ...

Canaloplasty has emerged as a viable surgical intervention for the management of open-angle glaucoma, offering an alternative to traditional procedures such as trabeculectomy. This non-penetrating ...